---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-010779"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:20:01.341384+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bioventus amends credit agreement: new leverage ratio 5.65x-4.00x, interest coverage 1.75x-3.00x, $10M liquidity

## Summary
- Bioventus LLC entered into Amendment No. 5 to Credit and Guaranty Agreement on Jan 18, 2024 with lenders and Wells Fargo as agent.
- Maximum debt leverage ratio: 5.65x for Mar 2024, stepping down to 4.00x from Jun 2025 onward.
- Minimum interest coverage ratio: 1.75x from Mar 2024, stepping up to 3.00x from Dec 2025 onward.
- New liquidity covenant requires at least $10M average daily balance per month through Oct 2025.
- Borrower paid amendment fee of 0.2% of aggregate Term Loan and Revolving Credit exposure to consenting lenders.

## SEC filing metadata
- accession: 0001193125-24-010779
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000119312524010779/0001193125-24-010779-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000119312524010779/d709819d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-010779
- JSON: https://secwatch.observer/filing/0001193125-24-010779.json
- Plain text: https://secwatch.observer/filing/0001193125-24-010779.txt

## Key facts
- Material Agreements
  Bioventus Inc. amended Amendment No. 5 to the Credit and Guaranty Agreement with Wells Fargo Bank, National Association valued at Amended financial covenants: maximum debt leverage ratio from 5.65:1 to 4.00:1 over testing periods; (effective 2024-01-18).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Wells Fargo Bank, National Association
  - Value: Amended financial covenants: maximum debt leverage ratio from 5.65:1 to 4.00:1 over testing periods;
  - Effective: 2024-01-18
  source text: On January 18, 2024 (the “Closing Date”), Bioventus LLC (“Bioventus LLC”), a Delaware limited liability company and subsidiary of Bioventus Inc. (together with its subsidiaries, the “Company”) and certain of its subsidiaries entered into an Amendment No. 5 to the Credit and Guaranty Agreement (the “Fifth Amendment”) with Wells Fargo Bank, National Association, as administrative agent and collateral agent, and the lenders and other financial institutions party thereto, which amended the Credit and Guaranty Agreement, dated as of December 6, 2019 (the “2019 Credit Agreement,” and, as amended by that certain Amendment No. 1 to Credit and Guaranty Agreement, dated as of August 29, 2021, by the Second Amendment to Credit and Guaranty Agreement, dated as of October 29, 2021, by the Third Amendment to Credit and Guaranty Agreement, dated as of July 11, 2022, by the Fourth Amendment to Credit and Guaranty Agreement, dated as of March 31, 2023 and by the Fifth Amendment, the “Amended 2019 Credi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312524010779/0001193125-24-010779-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.